PROFILPELAJAR.COM

Nelivaptan
(IUPAC) ime
	(2S,4R)-1-[(3R)-5-chloro-1-(2,4-dimethoxyphenyl)sulfonyl-3-(2-methoxyphenyl)-2-oxo-indolin-3-yl]-4-hydroxy-N,N-dimethyl-pyrrolidine-2-carboxamide
Klinički podaci
Identifikatori
CAS broj	439687-69-1
ATC kod	?
PubChem	9895468
ChemSpider	8071134
Hemijski podaci
Formula	C30H32ClN3O8S
Mol. masa	630.11 g/mol
SMILES	eMolekuli & PubHem
InChI
	InChI=1S/C30H32ClN3O8S/c1-32(2)28(36)24-15-19(35)17-33(24)30(21-8-6-7-9-25(21)41-4)22-14-18(31)10-12-23(22)34(29(30)37)43(38,39)27-13-11-20(40-3)16-26(27)42-5/h6-14,16,19,24,35H,15,17H2,1-5H3/t19-,24+,30+/m1/s1 ; Key: NJXZWIIMWNEOGJ-WEWKHQNJSA-N
Farmakoinformacioni podaci
Trudnoća	?
Pravni status
Način primene	Oralno

Nelivaptan (INN^[4]), kod SSR-149,415, je selektivni i oralno aktivni ne-peptidni antagonist vazopresinskog receptora koji je selektivan za V1b podtip.^[5] Lek je bio u kliničkim ispitivanjima za tretman anksioznosti i depresija.^[6] Jula 2008, Sanofi-Aventis je objavio da je dalji razvoj ovog leka obustavljen.^[7]

Literatura

↑ Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.”. Drug Discov Today 15 (23-24): 1052-7. DOI:10.1016/j.drudis.2010.10.003. PMID 20970519. edit
↑ Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry 4: 217-241. DOI:10.1016/S1574-1400(08)00012-1.
↑ Hettne KM, Williams AJ, van Mulligen EM, Kleinjans J, Tkachenko V, Kors JA. (2010). „Automatic vs. manual curation of a multi-source chemical dictionary: the impact on text mining”. J Cheminform 2 (1): 3. DOI:10.1186/1758-2946-2-3. PMID 20331846. edit
↑ World Health Organization (2007). „International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 98”. WHO Drug Information 21 (4): 341.
↑ Griebel G, Simiand J, Serradeil-Le Gal C, Wagnon J, Pascal M, Scatton B, Maffrand JP, Soubrie P (2002). „Anxiolytic- and antidepressant-like effects of the non-peptide vasopressin V1b receptor antagonist, SSR149415, suggest an innovative approach for the treatment of stress-related disorders”. Proc. Natl. Acad. Sci. U.S.A. 99 (9): 6370–5. DOI:10.1073/pnas.092012099. PMC 122955. PMID 11959912.
↑ Serradeil-Le Gal C, Wagnon J, Tonnerre B, Roux R, Garcia G, Griebel G, Aulombard A (2005). „An overview of SSR149415, a selective nonpeptide vasopressin V(1b) receptor antagonist for the treatment of stress-related disorders”. CNS drug reviews 11 (1): 53–68. DOI:10.1111/j.1527-3458.2005.tb00035.x. PMID 15867952.
↑ „Second-quarter 2008 results”. Press Release. Sanofi-Aventis. 31. 07. 2008.. Arhivirano iz originala na datum 2008-12-06. Pristupljeno 10. 06. 2009. »It has been decided to discontinue the development of amibegron and SSR 149415 (a V1B receptor antagonist).«

Vanjske veze

	Portal Medicina
	Portal Hemija

MeSH SSR149415

[1] Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.”. Drug Discov Today 15 (23-24): 1052-7. DOI:10.1016/j.drudis.2010.10.003. PMID 20970519. edit

[2] Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry 4: 217-241. DOI:10.1016/S1574-1400(08)00012-1.

[3] Hettne KM, Williams AJ, van Mulligen EM, Kleinjans J, Tkachenko V, Kors JA. (2010). „Automatic vs. manual curation of a multi-source chemical dictionary: the impact on text mining”. J Cheminform 2 (1): 3. DOI:10.1186/1758-2946-2-3. PMID 20331846. edit

[4] World Health Organization (2007). „International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 98”. WHO Drug Information 21 (4): 341.

[pmid11959912-5] Griebel G, Simiand J, Serradeil-Le Gal C, Wagnon J, Pascal M, Scatton B, Maffrand JP, Soubrie P (2002). „Anxiolytic- and antidepressant-like effects of the non-peptide vasopressin V1b receptor antagonist, SSR149415, suggest an innovative approach for the treatment of stress-related disorders”. Proc. Natl. Acad. Sci. U.S.A. 99 (9): 6370–5. DOI:10.1073/pnas.092012099. PMC 122955. PMID 11959912.

[pmid15867952-6] Serradeil-Le Gal C, Wagnon J, Tonnerre B, Roux R, Garcia G, Griebel G, Aulombard A (2005). „An overview of SSR149415, a selective nonpeptide vasopressin V(1b) receptor antagonist for the treatment of stress-related disorders”. CNS drug reviews 11 (1): 53–68. DOI:10.1111/j.1527-3458.2005.tb00035.x. PMID 15867952.

[urlen.sanofi-aventis.com-7] „Second-quarter 2008 results”. Press Release. Sanofi-Aventis. 31. 07. 2008.. Arhivirano iz originala na datum 2008-12-06. Pristupljeno 10. 06. 2009. »It has been decided to discontinue the development of amibegron and SSR 149415 (a V1B receptor antagonist).«

[1]

[2]

[3]

[4]

[5]

[6]

[7]